A silent but accelerating health crisis—antimicrobial resistance—threatens to unravel modern medicine and poses a severe national security risk, yet the economic model for developing new antibiotics has collapsed. With drug-resistant infections already causing over a million deaths globally each year, and projections suggesting they could contribute to nearly 170 million deaths in the next quarter-century, the need for a policy solution is urgent.
The Economic Paradox of Antibiotics
The core problem is a market failure. Antibiotics are unique: their effectiveness diminishes with use as microbes adapt, requiring doctors to prescribe them sparingly. This prudent stewardship, while medically necessary, creates a tiny commercial market. Developing a single novel antibiotic can take over a decade and cost more than $1 billion, yet companies often face negative returns on investment, estimated at a loss of $50 million per drug. Consequently, major pharmaceutical firms have largely abandoned the field, and the small biotechs that remain are struggling for survival, with several going bankrupt shortly after gaining FDA approval.
This collapse comes despite antibiotics' immense value. They are the bedrock of modern healthcare, making routine surgeries, cancer treatments, and childbirth safe. Researchers estimate that developing new antibiotics and improving access could save the U.S. healthcare system $97 billion annually by 2050. The strategic vulnerability is also clear: a lack of effective antimicrobials leaves the military and civilian populations exposed to biological threats, placing the issue firmly in the realm of national security and strategic competition.
The PASTEUR Act's Subscription Model
To bridge this gap, a bipartisan group in Congress has reintroduced the Pioneering Antimicrobial Subscriptions to End Upsurging Resistance (PASTEUR) Act. The legislation would establish a subscription-style contract between the federal government and drug developers. Companies that successfully create novel antimicrobials targeting the most critical pathogens would receive a guaranteed, upfront payment, decoupling revenue from the volume of drugs sold. This provides the financial certainty needed to incentivize research and development while ensuring these lifesaving drugs are available when needed.
"The need to kickstart innovation has never been more urgent," said Phyllis Arthur, executive vice president at the Biotechnology Innovation Organization, in the original commentary. The data underscores this: of approximately 90 antibiotics in development in 2024, only five target the World Health Organization's "critical priority" pathogens. The PASTEUR Act is designed to directly address this innovation drought.
The crisis does not exist in a policy vacuum. It intersects with other pressing national challenges, from broader healthcare system overhauls to the economic disruptions caused by global instability that can divert attention and resources. Furthermore, the strain on public health infrastructure is multifaceted, mirroring pressures seen in other sectors like homeland security and transportation.
Failure to act carries profound consequences. Without a new economic model, the antibiotic pipeline will continue to dry up. This would not only create a direct healthcare catastrophe but also inflict severe economic damage and weaken national defense. The PASTEUR Act represents a critical test for Congress's ability to address a complex, long-term threat with a market-based policy solution. As with other looming crises, from synthetic opioids like cychlorphine to climate-driven events, preparedness is less costly than reaction.
Lawmakers now face a clear choice: pass the PASTEUR Act to build a sustainable defense against superbugs, or risk leaving the nation unprepared for a crisis where the cost of inaction is measured in millions of lives and trillions of dollars in economic impact.
